MetaCap

Coherus Oncology (CHRS) vs Tenaya Therapeutics (TNYA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Coherus Oncology (CHRS) has outperformed Tenaya Therapeutics (TNYA) over the past year, losing 68.1% versus a loss of 76.7%. Over five years, CHRS leads with a -98.0% price change compared with -98.5% for TNYA. Tenaya Therapeutics is the larger company by market cap ($65.3 million vs $57.1 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CHRS-68.12%TNYA-76.70%
+126%+20%-86%
Nov 21, 20251 yearNov 20, 2026
CHRS-98.00%TNYA-98.68%
+5%-49%-104%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CHRS versus TNYA key metrics
MetricCHRSTNYA
Share price$0.3698$0.2866
Market cap$57.15M$65.32M
1-day change-4.47%-3.99%
YTD return-73.96%-59.75%
1-year return-68.12%-76.70%
5-year return-97.99%-98.50%
EPS (TTM)$-1.12$-0.48
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$42.17M—
Revenue growth (YoY)+59.81%—
Net income (latest FY)$168.02M$-90.60M
Gross margin67.24%—
Operating margin-429.51%—
Net margin398.43%—
52-week high$2.62$1.46
52-week low$0.3628$0.28
Distance from 52-week high-85.86%-80.37%
Analyst consensusstrong_buynone
Avg. price target upside+1995.73%+1016.54%
Average volume1.80M2.96M
Shares outstanding154.54M227.93M
Employees14470
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Coherus Oncology

CHRS stock →

Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype (IgG1) monoclonal antibody targeting interleukin IL-27.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 144 employees

About Tenaya Therapeutics

TNYA stock →

Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. Its lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in Phase 1b/2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, which is in Phase 1b/2 clinical trial; and TN-301, a small molecule histone deacetylase-6 for heart failure with preserved ejection fraction that is in phase 1 clinical trial.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 70 employees

CHRS vs TNYA FAQ

Which is bigger, Coherus Oncology or Tenaya Therapeutics?

Tenaya Therapeutics (TNYA) is larger, with a market capitalization of $65.32M compared with $57.15M for Coherus Oncology (CHRS).

Which stock has performed better over the past year, CHRS or TNYA?

CHRS returned -68.12% over the past 12 months, compared with -76.70% for TNYA (price return, excluding dividends). Past performance does not predict future results.

Are Coherus Oncology and Tenaya Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons